This grant is for supporting translational and clinical research, including clinical trials, aimed at deepening our understanding of drug action, response, and safety. The primary focus is on pediatric patients across developmental stages, as well as pregnant women and the developing fetus. The overarching objective is to enhance the safety and effectiveness of current medications for these vulnerable populations. Furthermore, this funding seeks to foster the development of novel drugs or facilitate safer applications of existing therapies, ultimately enabling tailored treatments to address the unique clinical needs of children and obstetric patients. This initiative aims to fill critical knowledge gaps in specialized pharmacological care.
Opportunity ID: 239293
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-13-309 |
| Funding Opportunity Title: | Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.865 — Child Health and Human Development Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 05, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 16, 2016 |
| Current Closing Date for Applications: | Aug 16, 2016 |
| Archive Date: | Sep 16, 2016 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Special district governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Independent school districts County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education City or township governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in pregnant women and the developing fetus. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-13-309.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.865 | FORMS-C | Forms-C | PKG00182451 | Oct 19, 2013 | Jun 08, 2016 | View |
| FORMS-D | Use for due dates on or after May 25, 2016 | PKG00224064 | Jul 16, 2016 | Aug 16, 2016 | View |
Package 1
Mandatory forms
239293 RR_SF424_2_0-2.0.pdf
239293 PHS398_ResearchPlan_2_0-2.0.pdf
239293 PHS398_CoverPageSupplement_2_0-2.0.pdf
239293 RR_KeyPersonExpanded_2_0-2.0.pdf
239293 RR_OtherProjectInfo_1_3-1.3.pdf
239293 PerformanceSite_2_0-2.0.pdf
Optional forms
239293 RR_SubawardBudget30_1_3-1.3.pdf
239293 PlannedReport-1.0.pdf
239293 PHS398_CumulativeInclusionReport-1.0.pdf
239293 PHS398_ModularBudget_1_2-1.2.pdf
239293 RR_Budget_1_3-1.3.pdf
Package 2
Mandatory forms
239293 RR_SF424_2_0-2.0.pdf
239293 PHS398_CoverPageSupplement_3_0-3.0.pdf
239293 RR_OtherProjectInfo_1_3-1.3.pdf
239293 PerformanceSite_2_0-2.0.pdf
239293 RR_KeyPersonExpanded_2_0-2.0.pdf
239293 PHS398_ResearchPlan_3_0-3.0.pdf
Optional forms
239293 RR_Budget_1_3-1.3.pdf
239293 RR_SubawardBudget30_1_3-1.3.pdf
239293 PHS398_ModularBudget_1_2-1.2.pdf
239293 PHS_Inclusion_Enrollment_Report-1.0.pdf
239293 PHS_AssignmentRequestForm-1.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
